Mabwell (Shanghai) Bioscience Future Growth
Future criteria checks 2/6
Mabwell (Shanghai) Bioscience is forecast to grow earnings and revenue by 58.2% and 87.8% per annum respectively. EPS is expected to grow by 58.3% per annum. Return on equity is forecast to be -24.1% in 3 years.
Key information
58.2%
Earnings growth rate
58.3%
EPS growth rate
| Biotechs earnings growth | 43.4% |
| Revenue growth rate | 87.8% |
| Future return on equity | -24.1% |
| Analyst coverage | Low |
| Last updated | 13 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,779 | -138 | -29 | 43 | 5 |
| 12/31/2025 | 961 | -609 | -528 | -374 | 5 |
| 12/31/2024 | 326 | -903 | -789 | -966 | 5 |
| 9/30/2024 | 169 | -1,074 | -1,153 | -888 | N/A |
| 6/30/2024 | 153 | -1,085 | -1,209 | -923 | N/A |
| 3/31/2024 | 191 | -1,018 | -1,349 | -961 | N/A |
| 12/31/2023 | 128 | -1,053 | -1,283 | -783 | N/A |
| 9/30/2023 | 107 | -936 | -1,375 | -774 | N/A |
| 6/30/2023 | 107 | -945 | -1,479 | -777 | N/A |
| 3/31/2023 | 28 | -976 | -1,271 | -611 | N/A |
| 12/31/2022 | 28 | -955 | -1,264 | -719 | N/A |
| 9/30/2022 | 26 | -947 | -1,148 | -657 | N/A |
| 6/30/2022 | 20 | -853 | -932 | -550 | N/A |
| 3/31/2022 | 20 | -833 | -858 | -578 | N/A |
| 12/31/2021 | 16 | -770 | -640 | -422 | N/A |
| 9/30/2021 | 11 | -699 | -581 | -392 | N/A |
| 12/31/2020 | 5 | -643 | -646 | -515 | N/A |
| 12/31/2019 | 29 | -928 | -540 | -354 | N/A |
| 12/31/2018 | 37 | -225 | -380 | -156 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688062 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688062 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688062 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688062's revenue (87.8% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688062's revenue (87.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688062 is forecast to be unprofitable in 3 years.